| Statin use in acute coronary syndromes: cellular mechanisms and clinical evidence. | |
| | |
MedLine Citation:
|
PMID: 12441886 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE OF REVIEW: Review the cellular mechanisms and clinical evidence for the use of statins in patients with unstable coronary syndromes. RECENT FINDINGS: Clinical trials of statin therapy in acute coronary syndromes demonstrate a rapid improvement in endothelial function, improved perfusion to ischemic myocardium, and an early reduction in cardiovascular events. The early benefit of statin therapy is related to a combination of molecular mechanisms that involve the oxidized LDL receptor (LOX-1), endothelial localized nitric oxide synthase, inflammatory cytokines, interstitial collagenases, and tissue factor expression. In human atheroma, 3 months' use of statin (pravastatin) therapy reduced the content of oxidized LDL, inflammatory cells (macrophage, T cells) infiltrates, and improved plaque stability by increasing the collagen content of the fibrous cap. SUMMARY: The antiatherothrombotic effects of statin therapy appear to have important clinical relevance to patients with impaired myocardial perfusion and acute coronary syndrome. |
| | |
Authors:
|
Robert S Rosenson; Alan S Brown |
Related Documents
:
|
8602596 - Inverse relation between the concentration of low-density-lipoprotein vitamin e and sev... 14520026 - Higher content of 18:1 trans fatty acids in subcutaneous fat of persons with coronarogr... 2076386 - Excessive mural calcium overload--a predominant causal factor in the development of ste... 10769416 - Electron beam computed tomography: calcification and lipid lowering interventions. 16018836 - Incidence and prognostic impact of gastrointestinal bleeding after percutaneous coronar... 10483956 - Acute myocardial infarction with isolated st-segment elevation in posterior chest leads... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Current opinion in lipidology Volume: 13 ISSN: 0957-9672 ISO Abbreviation: Curr. Opin. Lipidol. Publication Date: 2002 Dec |
Date Detail:
|
Created Date: 2002-11-20 Completed Date: 2003-06-12 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9010000 Medline TA: Curr Opin Lipidol Country: England |
Other Details:
|
Languages: eng Pagination: 625-30 Citation Subset: IM |
Copyright Information:
|
Copyright 2002 Lippincott Williams & Wilkins |
Affiliation:
|
Preventive Cardiology Center, Division of Cardiology, Department of Medicine, Northwestern University, The Feinberg School of Medicine, Chicago, IL 60611, USA. r-rosenson@nothwestern.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acute Disease Clinical Trials as Topic Coronary Disease / drug therapy* Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology*, therapeutic use* Syndrome Time Factors Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Lipid-lowering therapy in people with type 2 diabetes.
Next Document: Early initiation of statin therapy after a coronary event.